metaCOVID

metaCOVID performs living meta-analyses of randomized controlled trials (RCTs) for COVID-19 treatments and vaccines to provide up-to-date quantitative synthesis.

Key Features:

• Living Evidence Synthesis: Built on the COVID-NMA platform (https://covid-nma.com/) to enable continuous updates and refinements of meta-analyses as new RCT data become available.
• Exploratory Analyses: Enables user-driven exploratory analyses of trial data to examine specific comparisons and outcomes.
• Automation: Automates aspects of data aggregation and analysis to accelerate update cycles and reduce manual processing.
• Customizable Subgroup and Sensitivity Analyses: Supports subgroup analyses and sensitivity checks to examine heterogeneity and robustness of pooled estimates.
• Forest Plot Output: Produces downloadable forest plots for standardized presentation of meta-analysis results.

Scientific Applications:

• Support for researchers: Aggregates RCT findings on COVID-19 treatments and vaccines to support research and evidence synthesis.
• Clinical and guideline support: Provides pooled estimates that can inform clinical decision-making and guideline development for COVID-19 interventions.
• Policy formulation: Supplies up-to-date synthesized evidence to inform public health and policy decisions on COVID-19 treatments and vaccines.

Methodology:

Developed in R with an R-Shiny implementation; integrates with the COVID-NMA platform and uses automated update processes and analysis routines to generate meta-analytic summaries and downloadable forest plots.